Cited 5 time in
A review on Millepachine and its derivatives as potential multitarget anticancer agents
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rampogu, Shailima | - |
| dc.contributor.author | Badvel, Pallavi | - |
| dc.contributor.author | Hoon Jo, Byung | - |
| dc.contributor.author | Kim, Yongseong | - |
| dc.contributor.author | Kim, Seon-Won | - |
| dc.contributor.author | Lee, Keun Woo | - |
| dc.date.accessioned | 2023-10-25T08:41:50Z | - |
| dc.date.available | 2023-10-25T08:41:50Z | - |
| dc.date.issued | 2023-11 | - |
| dc.identifier.issn | 0006-291X | - |
| dc.identifier.issn | 1090-2104 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/68247 | - |
| dc.description.abstract | Chalcones have a long history of being used for many medical purposes. These are the most prestigious scaffolds in medicine. The potential of Millepachine and its derivatives to treat various malignancies has been demonstrated in this review. The anticancer effects of Millepachine and its derivatives on ovarian cancer, hepatocellular carcinoma, breast, liver, colon, cervical, prostate, stomach, and gliomas are highlighted in the current review. Several genes that are crucial in reducing the severity of the disease have been altered by these substances. They mainly work by preventing tubulin polymerizing. They also exhibit apoptosis and cell cycle arrest at the G2/M phase. Additionally, these compounds inhibit invasion and migration and have antiproliferative effects. Preclinical studies have shown that Millepachine and its derivatives offer exceptional potential for treating a number of cancers. These results need to be confirmed in clinical research in order to develop viable cancer therapies. © 2023 Elsevier Inc. | - |
| dc.format.extent | 22 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Academic Press | - |
| dc.title | A review on Millepachine and its derivatives as potential multitarget anticancer agents | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.bbrc.2023.09.044 | - |
| dc.identifier.scopusid | 2-s2.0-85173186369 | - |
| dc.identifier.wosid | 001149605700001 | - |
| dc.identifier.bibliographicCitation | Biochemical and Biophysical Research Communications, v.681, pp 249 - 270 | - |
| dc.citation.title | Biochemical and Biophysical Research Communications | - |
| dc.citation.volume | 681 | - |
| dc.citation.startPage | 249 | - |
| dc.citation.endPage | 270 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Biophysics | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Biophysics | - |
| dc.subject.keywordPlus | TUBULIN POLYMERIZATION | - |
| dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
| dc.subject.keywordPlus | CHALCONE DERIVATIVES | - |
| dc.subject.keywordPlus | IN-VITRO | - |
| dc.subject.keywordPlus | APOPTOSIS | - |
| dc.subject.keywordPlus | PATHWAY | - |
| dc.subject.keywordPlus | HYBRIDS | - |
| dc.subject.keywordPlus | DISCOVERY | - |
| dc.subject.keywordPlus | DESIGN | - |
| dc.subject.keywordAuthor | G2/M arrest | - |
| dc.subject.keywordAuthor | Millepachine | - |
| dc.subject.keywordAuthor | Millepachine and its derivatives | - |
| dc.subject.keywordAuthor | Natural compounds | - |
| dc.subject.keywordAuthor | Tubulin polymerization | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
